<DOC>
	<DOCNO>NCT00827619</DOCNO>
	<brief_summary>This study intend evaluate long-term effectiveness treatment de novo restenotic lesion above-the-knee femoropopliteal artery use Zilver® Flex™ Vascular Stent receive CE mark commercial use . The study design single arm non-randomized post-approval study .</brief_summary>
	<brief_title>Zilver® Flex™ Vascular Stent Study</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Patients least 18 year old least 1 stenotic atherosclerotic lesion abovetheknee femoropopliteal artery may consider enrollment . To enrol study , lesion must appropriate size prior stent target vessel may present . Patient &lt; 18 year age . Patient pregnant breastfeeding . Patient simultaneously participate investigational drug device study . The patient must complete followup phase primary endpoint previous study least 30 day prior enrollment study . Patient previous stenting target vessel . Patient medical condition disorder would limit life expectancy le 1 year may cause noncompliance protocol confound data analysis . Patient antiplatelet and/or anticoagulant therapy contraindicate . Patient history bleed diathesis coagulopathy refuse blood transfusion . Patient known hypersensitivity contraindication aspirin , antiplatelet medication , contrast dye , nitinol , opinion investigator , adequately premedicated .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
</DOC>